Knight Therapeutics Inc traded at 5.34 this Thursday June 30th, decreasing 0.01 or 0.19 percent since the previous trading session. Looking back, over the last four weeks, Knight Therapeutics Inc lost 2.20 percent. Over the last 12 months, its price rose by 1.52 percent. Looking ahead, we forecast Knight Therapeutics Inc to be priced at 5.22 by the end of this quarter and at 4.87 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
5.34
Daily Change
-0.19%
Yearly
1.52%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Aerie Pharmaceuticals 8.36 0.86 11.47% -47.78%
Omeros 4.64 1.89 68.73% -69.05%

Indexes Price Day Year
CATSX 18861 -217.28 -1.14% -6.75%

Knight Therapeutics Inc
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.